• AnTolRx

  Participated · Series A · Sep 2016

  AnTolRx, Inc. is a Cambridge, Mass.-based developer of treatments for autoimmune diseases centered on antigen-specific Targeted Nanoparticle Tolerance Therapeutics (TNTT). Its TNTT platform is intended to treat immune disorders including type 1 diabetes and is based on the work of Dr. Francisco Quintana. The company is led by Mark Carthy, Chief Executive Officer. AnTolRx closed a Series A financing totaling $4M to support its development efforts. The company intends to use the funds for research and development of its TNTT approach over the next two years.

• Lysosomal Therapeutics

  Participated · Series A · Feb 2015

  Lysosomal Therapeutics (LTI) develops small molecules that cross the blood–brain barrier to increase glucocerebrosidase (GCase) activity and address lysosome-linked neurodegeneration. Its lead program targets Gaucher-related neurodegeneration, Parkinson’s disease and other synucleinopathies. The company plans to advance its GCase activator candidate toward a clinical start while expanding its platform to explore other lysosomal enzyme deficiencies and genetic links to common neurodegenerative disorders. Recent funding will support compound optimization, preclinical development and a biomarker initiative intended to help select patients for trials and predict drug response. LTI has previously received grant funding from The Michael J. Fox Foundation for Parkinson’s Research to support the biomarker effort. To support platform expansion and partnering, LTI has hired Darren Braccia as vice president of business development. Lysosomal Therapeutics (LTI) leverages lysosomal biology to discover small molecules that increase glucocerebrosidase (GCase) activity and normalize lysosomal function in neurons. Its lead program targets Gaucher-related neurodegeneration, Parkinson’s disease and other synucleinopathies with compounds designed to cross the blood‑brain barrier. The company’s discovery work originated in Dimitri Krainc’s lab at Massachusetts General Hospital and continues with collaborators at Northwestern University. LTI plans to advance its GCase modulator platform through lead generation and into preclinical development. The firm is also investigating other lysosomal enzyme deficiencies and their links to common neurodegenerative diseases. LTI was founded by Krainc and former Genzyme executives Henri Termeer, Bob Carpenter and Peter Wirth; Kees Been is CEO. The company recently secured seed funding to support near‑term R&D and program advancement.

No current team members are available.